Orbis Investment Management
Orbis Investment Management Limited is a privately owned investment manager based in Hamilton, Bermuda, founded in 1989. The firm specializes in managing long-only and absolute return investment strategies for institutions and individuals, focusing on separate client-focused equity and balanced portfolios, as well as mutual funds. Orbis invests globally in public equity and fixed income markets, including regions such as Asia ex-Japan and Japan, with a particular emphasis on value stocks. The firm employs both fundamental and quantitative analysis, utilizing a bottom-up approach to inform its investment decisions. Orbis is committed to delivering value-for-money to its clients and benchmarks its portfolio performance against various MSCI indices, TOPIX, and the JP Morgan Global Government Bond Index. The company manages approximately $30 billion in assets and employs around 400 professionals from diverse backgrounds across eight countries, reflecting a rich tapestry of nationalities and expertise.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
3 past transactions
Nebius AI
Post in 2024
Nebius AI is an AI-centric public cloud platform, launched in late 2023 and specifically crafted to serve AI models from ML training to inferencing at a scale.
Our mission is to enable ML practitioners to concentrate on their core job while DevOps, MLOps and infrastructure related tasks are on us. Our goal is to build an ML-specific cloud platform covering the whole ML lifecycle from A to Z: from data preparation and data labeling to ML training and inference.
RXO
Post in 2024
RXO is a market leader in asset-light transportation. It develops more efficient freight transportation methods for shippers and carriers.
Peplin
Private Equity Round in 2008
Peplin is a development-stage specialty pharmaceutical company dedicated to advancing medical dermatology products. The company focuses on PEP005, a compound derived from Euphorbia peplus, which is utilized in its lead product, a patient-applied topical gel currently in Phase III clinical trials for the treatment of actinic keratosis. Additionally, Peplin is developing a physician-applied topical gel for superficial basal cell carcinoma, also based on PEP005. The active ingredient in both products is a small molecule extracted and purified from the sap of Euphorbia peplus. Peplin's commitment to addressing skin disorders is further underscored by its acquisition of Neosil, Inc., a dermatology-focused company, before eventually being acquired by LEO Pharma A/S.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.